The trace amine-associated receptor 1 agonists – non-dopaminergic antipsychotics or covert modulators of D2 receptors?
Journal of Psychopharmacology · 2024
DOI: 10.1177/02698811241249415 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Psychopharmacology, 2024. Verfasst von Gavin P Reynolds. Beteiligte Einrichtung: Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK. Hauptthemen laut MEDLINE: Antipsychotic Agents, Receptors, Dopamine D2, Schizophrenia, Receptors, G-Protein-Coupled. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
A major effort of the pharmaceutical industry has been to identify and market drug treatments that are effective in ameliorating the symptoms of psychotic illness but without the limitations of the current treatments acting at dopamine D2 receptors. These limitations include the induction of a range of adverse effects, the inadequate treatment response of a substantial proportion of people with schizophrenia, and the generally poor response to negative and cognitive features of the disease. Recently introduced drug treatments have gone some way to avoiding the first of these, with a reduced propensity for weight gain, cardiovascular risk and extrapyramidal motor effects. Despite claims of some small improvements in negative symptoms, these drugs have not demonstrated substantial increases in efficacy. Of the drugs currently in development as antipsychotic agents, several are misleadingly described as having novel ‘non-dopaminergic’ mechanisms that may offer improvements in addressing the limitations of adverse effects and efficacy. It will be argued, using the trace amine-associated receptor 1 agonist as an example, that several of these new drugs still act primarily through modulation of dopaminergic neurotransmission and, in not addressing the primary pathology of schizophrenia, are therefore unlikely to have the much-needed improvements in efficacy required to address the unmet need associated with resistance to current treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK.
- Rotherham Doncaster and South Humber NHS Foundation Trust, Doncaster, UK.
ORCID-Profile: Gavin P Reynolds
Zitieren
APA
Reynolds, G. P. (2024). The trace amine-associated receptor 1 agonists – non-dopaminergic antipsychotics or covert modulators of D2 receptors?. Journal of Psychopharmacology. https://doi.org/10.1177/02698811241249415
Vancouver
Reynolds GP. The trace amine-associated receptor 1 agonists – non-dopaminergic antipsychotics or covert modulators of D2 receptors?. Journal of Psychopharmacology. 2024. doi:10.1177/02698811241249415
BibTeX
@article{Reynolds2024,
author = {Reynolds, Gavin P},
title = {The trace amine-associated receptor 1 agonists – non-dopaminergic antipsychotics or covert modulators of D2 receptors?},
journal = {Journal of Psychopharmacology},
year = {2024},
doi = {10.1177/02698811241249415}
}
EUVIMED